Andersen Kim Francis, Fuglo Hanna Maria, Rasmussen Sine Hvid, Petersen Michael Mork, Loft Annika
From the Department of Clinical Physiology, Nuclear Medicine & PET (KFA, SHR, AL); and Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (HMF, MMP).
Medicine (Baltimore). 2015 Dec;94(51):e2319. doi: 10.1097/MD.0000000000002319.
The aim of the study is to assess the prognostic value of different volume-based calculations of tumor metabolic activity in the initial assessment of patients with high-grade bone sarcomas (BS) and soft tissue sarcomas (STS) using F-18 FDG PET/CT.A single-site, retrospective study from 2002 to 2012 including 92 patients with histologically verified high-grade BS (N = 37) or STS (N = 55). All patients underwent a pretreatment F-18 FDG PET/CT scan. Clinical data were registered. Measurements of the accuracy of metabolic tumor volume with a preset threshold of 40% of the maximum standardized uptake value of primary tumor (MTV40%) and total lesion glycolysis (TLG) as prognostic variables and identification of optimal discriminating cut-off values were performed through ROC curve analysis. Patients were grouped according to the cut-off values. All deaths were considered an event in survival analysis. Kaplan-Meier survival estimates and log-rank test were used to compare the degree of equality of survival distributions. Prognostic variables with related hazard ratios (HR) were assessed using Cox proportional hazards regression analysis.Forty-one of 92 patients died during follow-up (45%; 12 BS and 29 STS). Average survival for included patients was 6.5 years (95% CI 5.8-7.3 years) and probability of 5-year survival was 52%. There was a high-significant accuracy of TLG and MTV40% as prognostic variables when looking on all patients and during subgroup analysis. AUCs were higher for TLG than for MTV40%. TLG above optimal cut-off value was the only variable which was independently prognostic for survival throughout multivariate regression analysis of all included patients (P = 0.01, HR 4.78 [95% CI 1.45-15.87]) and subgroup analysis (BS: P = 0.04, HR 11.11 [95% CI 1.09-111.11]; STS: P < 0.05, HR 3.37 [95% CI 1.02-11.11]). No significant results were demonstrated for MTV40%.Volume-based F-18 FDG PET/CT imaging markers in terms of pretreatment estimation of TLG provide supplemental prognostic information to histologic grading, with significant independent properties for prediction of overall survival in patients with high-grade BS or STS.
本研究旨在通过F-18 FDG PET/CT评估不同基于体积的肿瘤代谢活性计算方法在高级别骨肉瘤(BS)和软组织肉瘤(STS)患者初始评估中的预后价值。这是一项2002年至2012年的单中心回顾性研究,纳入92例经组织学证实的高级别BS患者(n = 37)或STS患者(n = 55)。所有患者均接受了治疗前F-18 FDG PET/CT扫描,并记录临床数据。以原发肿瘤最大标准化摄取值的40%为预设阈值测量代谢肿瘤体积(MTV40%)和总病变糖酵解(TLG),将其作为预后变量,并通过ROC曲线分析确定最佳鉴别临界值。根据临界值对患者进行分组。在生存分析中,所有死亡均视为事件。采用Kaplan-Meier生存估计和对数秩检验比较生存分布的相等程度。使用Cox比例风险回归分析评估具有相关风险比(HR)的预后变量。92例患者中有41例在随访期间死亡(45%;12例BS和29例STS)。纳入患者的平均生存期为6.5年(95%CI 5.8 - 7.3年),5年生存率为52%。在对所有患者及亚组分析中,TLG和MTV40%作为预后变量具有高度显著的准确性。TLG的AUC高于MTV40%。在所有纳入患者的多因素回归分析(P = 0.01,HR 4.78 [95%CI 1.45 - 15.87])和亚组分析(BS:P = 0.04,HR 11.11 [95%CI 1.09 - 111.11];STS:P < 0.05,HR 3.37 [95%CI 1.02 - 11.11])中,高于最佳临界值的TLG是唯一对生存具有独立预后意义的变量。MTV40%未显示出显著结果。基于体积的F-18 FDG PET/CT成像标志物在治疗前TLG评估方面为组织学分级提供了补充预后信息,对高级别BS或STS患者的总生存预测具有显著的独立特性。